Bleeding is the most common complication of anticoagulant use. And to better care for patients either experiencing acute bleeding or urgently needing surgery, it's critical that clinicians thoroughly understand how to assess, treat, and reverse anticoagulation. Dr. Jennifer Caudle sits down with Dr. Aryeh Shander to discuss some of the different considerations we should take into account when selecting a warfarin reversal option.

Please read full Prescribing Information for Kcentra®.

KCT-0033-APR21

Axial psoriatic arthritis (axPsA) is a challenging clinical entity to characterize, with a prevalence ranging anywhere between 12.5% and 78% of psoriatic arthritis patients because of varied definitions and inclusion criteria. To learn more about how we can better define and diagnose axPsA, Dr. Matt Birnholz is joined by Dr. Alexis Ogdie, Associate Professor of Medicine and Epidemiology at the University of Pennsylvania.

4/21 M-XAT-1400586

Prostate cancer is one of the most common cancers in men in the United States. In a program sponsored by Astellas and Pfizer, Drs. Maha Hussain and Christopher Evans discuss the history and how care is evolving for men with metastatic prostate cancer and non-metastatic castration-resistant prostate cancer.

This program is intended for United States health care professionals only. Drs. Hussain and Evans have recevied compensation from Astellas and Pfizer for their time.

074-0391-PM

Is it time to connect the dots between systemic juvenile idiopathic arthritis (SJIA) and adult-onset Still’s disease (AOSD)? There is a growing recognition that SJIA and AOSD represent the same disease continuum with different ages of onset.1 Both conditions are rare autoinflammatory disorders of unknown etiology.1 In addition to Still’s disease rarity, patients present with varying symptoms and are diagnosed by exclusion of other diseases, which may result in a long time to proper care.2,3 A delay in diagnosis and failure to control disease activity can lead to severe and life-threatening complications.4 A multidisciplinary team effort and greater disease awareness are necessary to help expedite the therapeutic journey of patients with Still’s disease.5

Listen in to a discussion panel moderated by Christopher T. Ritchlin, MD with Petros Efthimiou, MD and Olga Petryna, MD as they have a conversation on the concept of the continuum of Still’s disease, its burden, and the patient journey.

This presentation is sponsored by Novartis Medical Affairs and all speakers have been compensated for their time.

References

1. Vastert SJ, Jamilloux Y, Quartier P, et al. Anakinra in children and adults with Still’s disease. Rheumatology. 2019;58(suppl 6):vi9-vi22. doi:10.1093/rheumatology/kez350
2. Efthimiou P. Diagnosis and management of adult onset …

Can you put the puzzle together in axial spondyloarthritis (axSpA) and axial psoriatic arthritis (axPsA)?

Axial involvement is an important feature in patients with SpA and PsA, and this manifestation has various similarities and differences between both diseases.1,2 Recognizing and assessing the unique presentation of axPsA and axSpA is critical to improve the outcomes in our patients.

Listen in to a discussion panel moderated by Christopher T. Ritchlin, MD with Atul Deodhar, MD, Philip Mease, MD, and Alexis Ogdie-Beatty, MD, as they discuss current diagnostic challenges and new insights on the assessment of axial features.

This presentation is sponsored by Novartis Medical Affairs and all speakers have been compensated for their time.

References

1. Feld J, Chandran V, Haroon N, Inman R, Gladman D. Axial disease in psoriatic arthritis and ankylosing spondylitis: A critical comparison. Nat Rev Rheumatol. 2018;14(6):363-371. doi:10.1038/s41584-018-0006-8
2. Helliwell PS. Axial disease in psoriatic arthritis. Rheumatology. 2019:1-3. doi:10.1093/rheumatology/kez629

3/21 M-XAT-1399851​

Catch up on the top abstracts related to Still’s disease that were presented at ACR Convergence 2020 with Dr. Bella Mehta from Cornell Hospital for Special Surgery and Dr. Olga Petryna from NYU Langone Medical Center.

This presentation is sponsored by Novartis Medical Affairs and all speakers have been compensated for their time.

3/21 M-XAT-1399851​

Join Dr. Laura Coates from the University of Oxford and Dr. Alexis Ogdie from the University of Pennsylvania as they walk us through the top abstracts on spondyloarthritis that were presented at ACR Convergence 2020.

This presentation is sponsored by Novartis Medical Affairs and all speakers have been compensated for their time.

3/21 M-XAT-1399851​

Since adults 65 years and older bear the greatest burden of severe disease from influenza, it’s critically important to ask ourselves the following question: what can we do to better prevent seasonal influenza infections in older adults? Here to answer that and other practical questions is Dr. Archana Chatterjee, MD, PhD, Dean of the Chicago Medical School and Vice President for Medical Affairs at Rosalind Franklin University in Chicago, IL.

USA-CRP-21-0004 January 2021

Pathologist Fernando Uriel Garcia, MD provides his perspective on the importance of the biomarkers in determining patient prognosis and potential implications depending on a patient's biomarker status.

© 2021 Pfizer Inc. All rights reserved. PP-BCE-USA-0289 April 2021

The anti-apoptotic protein B-cell lymphoma 2 (BCL2) is a key regulator of the intrinsic apoptotic pathway and is often overexpressed in chronic lymphocytic leukemia (CLL) cells. That’s why BCL2 represents an important therapeutic target for CLL, and joining Dr. Charles Turck to look at Venetoclax, a treatment option that targets this protein is Dr. Nicole Lamanna, an Associate Clinical Professor of Medicine at Columbia University Medical Center in New York.